Pharmaceutical Market China and Medical Device Market South Korea
We remain bullish on China's pharmaceutical sector despite the slowdown in the economy and political reshuffle. We do not think the reshuffle will have any adverse changes or cause any reversals to healthcare reform given that the country has been rolling out various healthcare schemes in 2012 and that a key person overseeing these healthcare reform plans is Vice Premier Li Keqiang, the man who may potentially take over from Premier Wen Jiabao in the reshuffle. However, the business environment will potentially be threaten by cost- containment policies as the country will have to contain its ever-growing healthcare expenditure.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/the-pharmaceutical-market-china
Headline Expenditure Projections
• Pharmaceuticals: CNY432bn (US66.7bn) in 2011to CNY521bn (US$82.2bn) in 2012; +20.6% in local currency and +23.0% in US dollar terms. Forecast broadly in line with Q412.
• Healthcare: CNY2313bn (US$358bn) in 2011 to CNY2,602bn (US$410bn) in 2012; +12.5% in local currency terms and +14.7% in US dollar terms. Forecast broadly in line with Q412.
• Medical Devices: CNY117bn (US$18.2bn) in 2011 to CNY146bn (US$22.8bn) in 2012; +24.3% in local currency terms and +26.7% in US dollar terms. Forecast broadly in line with Q412.
China continues to rank fourth out of the 18 key markets in BMI's Q113 Asia Pacific Pharmaceutical Risk/Reward Ratings with an unchanged score of 62.5 Its high ranking on the table (just behind developed markets Japan, South Korea and Australia) is largely due to the strong growth potential of the pharmaceutical market that is underpinned by a large and increasingly affluent population and an increasing burden of non-communication diseases.
Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/207536